Media headlines about Entellus Medical (NASDAQ:ENTL) have been trending somewhat positive recently, Accern reports. The research firm ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Entellus Medical earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned headlines about the medical technology company an impact score of 45.5016359061801 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Several equities research analysts have weighed in on the company. BidaskClub raised Entellus Medical from a “strong sell” rating to a “sell” rating in a research note on Monday, February 5th. Zacks Investment Research cut Entellus Medical from a “hold” rating to a “sell” rating in a research note on Wednesday, January 24th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $20.33.

How to Become a New Pot Stock Millionaire

NASDAQ ENTL traded down $0.01 during trading hours on Tuesday, hitting $24.00. 43,800 shares of the company were exchanged, compared to its average volume of 178,331. Entellus Medical has a 52 week low of $11.47 and a 52 week high of $25.58. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.92 and a quick ratio of 1.71.

TRADEMARK VIOLATION WARNING: “Entellus Medical (ENTL) Earning Somewhat Favorable Press Coverage, Study Finds” was reported by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://www.dailypolitical.com/2018/04/17/entellus-medical-entl-earning-somewhat-favorable-press-coverage-study-finds.html.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.